16 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 10 with minor changes only.
Primary completion pushed from Nov 2026 to Jul 2030
And 2 more changes in the last 30 days
Gilead SciencesPhase 2/3 NCT06532656 Registry history of NCT06532656 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2029 to Sep 2030
Kite, A Gilead CompanyPhase 1 NCT07038447 Registry history of NCT07038447 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial arms changed: 2 → 3
Kite, A Gilead CompanyPhase 1 NCT07304154 Registry history of NCT07304154 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Sponsor changed: Arcellx, Inc. to Kite, A Gilead Company; Interventions modified
Kite, A Gilead CompanyPhase 1 NCT05457010 Registry history of NCT05457010 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Enrollment increased: 1000 → 1500 participants; Interventions modified
Kite, A Gilead CompanyNot specified NCT05041309 Registry history of NCT05041309 on ClinicalTrials.gov (opens the registry)
Primary completion moved earlier from Mar 2034 to Jun 2027
Gilead SciencesPhase 4 NCT06337032 Registry history of NCT06337032 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 2026 to Feb 2027
Gilead SciencesPhase 1 NCT06562907 Registry history of NCT06562907 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 372 → 376 locations
Gilead SciencesPhase 3 NCT05633654 Registry history of NCT05633654 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 16 locations
Gilead SciencesPhase 2/3 NCT07708727 Registry history of NCT07708727 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 42 locations
Kite, A Gilead CompanyPhase 3 NCT07479797 Registry history of NCT07479797 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 213 → 217 locations
Gilead SciencesPhase 3 NCT06051617 Registry history of NCT06051617 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 28 → 34 locations
Kite, A Gilead CompanyPhase 1/2 NCT04989803 Registry history of NCT04989803 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 15 locations
Gilead SciencesPhase 2 NCT07546812 Registry history of NCT07546812 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 16 locations
Gilead SciencesPhase 1 NCT07719491 Registry history of NCT07719491 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jan 2027 to Jan 2028
Gilead SciencesPhase 2/3 NCT04150068 Registry history of NCT04150068 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Nov 2026 to Jun 2027
Gilead SciencesPhase 2/3 NCT02881320 Registry history of NCT02881320 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-25 | NCT07841977 Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis | Phase 2 | Not Yet Recruiting |
| 2026-09-25 | NCT07841990 Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1… | Phase 2 | Not Yet Recruiting |
| Phase 1 | 19 | |
| Phase 1/2 | 8 | |
| Phase 2 | 25 | |
| Phase 2/3 | 7 | |
| Phase 3 | 24 | |
| Phase 4 | 1 |
Breast Cancer (9) · Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (8) · Non-Hodgkin Lymphoma (7) · Triple-Negative Breast Cancer (7) · DLBCL (3) · Leukemia (3) · Multiple Myeloma (3) · Acute Lymphoblastic Leukemia (ALL) (2) · Bladder Cancer (2)